March 01, 2015 10:44 AM ET

Biotechnology

Company Overview of GlobeImmune Inc.

Company Overview

GlobeImmune Inc., a biopharmaceutical company, develops therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidates include GI-4000, which is in Phase II clinical trials for the treatment of colorectal cancer and non-small cell lung cancer, as well as in Phase IIb clinical trial for the treatment of pancreas cancer; GI-6207 that is a Phase II clinical trial product candidate for the treatment of human epithelial cancers, including non-small cell lung cancer, colorectal, pancreas, breast, gastric, and medullary thyroid cancers; GI-6301, a Phase I clinical trial Tarmogen designed to target cancers expressing the brachyury protein, such...

1450 Infinite Drive

Louisville, CO 80027

United States

Founded in 1995

24 Employees

Phone:

303-625-2700

Fax:

303-625-2710

Key Executives for GlobeImmune Inc.

Chief Executive Officer, President and Director
Age: 63
Total Annual Compensation: $388.1K
Principal Financial & Accounting Officer, Vice President of Finance, Secretary and Treasurer
Age: 49
Total Annual Compensation: $191.5K
Vice President of Corporate Development
Age: 45
Total Annual Compensation: $188.8K
Compensation as of Fiscal Year 2013.

GlobeImmune Inc. Key Developments

GlobeImmune Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 03:00 PM

GlobeImmune Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 03:00 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Timothy C. Rodell, Chief Executive Officer, President and Director.

GlobeImmune Inc. Announces Earnings Results for the Quarter and Nine Months Ended September 30, 2014

GlobeImmune Inc. announced earnings results for the quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss of $6.4 million compared to $0.7 million a year ago. For the nine months the company reported net loss of $14.5 million compared to $1.2 million a year ago. The increase in the net losses was primarily due to non-cash interest expense and early retirement associated with convertible notes and fair-value adjustments of warrants. These non-cash expenses terminated upon closing of the initial public offering.

Globeimmune Announce Updated Results from Eleven Chordoma Patients in the GI-6301 Phase 1 Trial

GlobeImmune Inc. announced that updated results from eleven chordoma patients in the GI-6301 Phase 1 trial were presented at the 2014 CTOS Annual Meeting in Berlin, Germany. Christopher R. Heery, M.D., Head, Clinical Trials Group, Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI) presented the data during his talk entitled "NCI Experience Using Yeast-Brachyury Vaccine (GI-6301) in Patients with Advanced Chordoma (Paper 030)". The GI-6301 Tarmogen(R) product candidate targets cancers containing the brachyury protein. The NCI is conducting a Phase 1 safety, immunology and early efficacy trial of GI-6301 monotherapy in patients with late-stage cancers known to express the brachyury protein including chordoma. This presentation updates data GlobeImmune previously reported on seven chordoma patients in the trial. Results to date from the eleven chordoma patients in this trial include: GI-6301 has been generally well tolerated, immunogenic, and has shown evidence of clinical activity in both advanced epithelial cancers and chordomas. Summary results: One confirmed partial response by RECIST that has continued past one year. Eight patients with stable disease at day 85 restaging; Two of these patients had stable disease at study entry; Study status; Seven of 11 chordoma patients have left the study due to disease progression; Four of 11 chordoma patients remain on treatment with stable disease; Three of these four patients had progressive disease at study entry; 62% of all patients (all tumor types) evaluated to date in this Phase 1 trial had post-administration brachyury-specific T cell immune responses; The most common adverse events seen in this trial were mild/moderate injection site reactions.

Similar Private Companies By Industry

Company Name Region
Success by Association United States
HyClone Laboratories, Inc. United States
TEI Biosciences Inc. United States
AxoTect, Inc. United States
BIO Wellness, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GlobeImmune Inc., please visit www.globeimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.